New drug aims to ease severe facial pain in trigeminal neuralgia
NCT ID NCT06571448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called SR750 in 138 people with trigeminal neuralgia, a condition that causes sudden, severe facial pain. Participants took either SR750 or a placebo for 6 weeks and recorded their daily pain levels. The goal was to see if SR750 reduces pain better than a placebo and is safe to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIGEMINAL NEURALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pain relief showdown: one drug vs. two for facial nerve pain
- New combo therapy aims to calm face pain attacks
- Laser showdown: which light therapy zaps facial pain best?
- Massive study aims to predict brain surgery success
- Magnetic pulses to the brain may ease stubborn nerve pain
- AI and VR join forces to fight severe facial pain